CX-4945, a selective inhibitor of casein kinase-2 (CK2), exhibits anti-tumor activity in hematologic malignancies including enhanced activity in chronic lymphocytic leukemia when combined with fludarabine and inhibitors of the B-cell receptor pathway

Inhibitors of B-Cell Receptor Signaling for Patients With B-Cell Malignancies

(2012) Michael Y. Choi et al.   CANCER JOURNAL

Protein kinase CK2 in hematologic malignancies: reliance on a pivotal cell survival regulator by oncogenic signaling pathways

(2012) F Piazza et al.   LEUKEMIA

CK2 Inhibitor CX-4945 Suppresses DNA Repair Response Triggered by DNA-Targeted Anticancer Drugs and Augments Efficacy: Mechanistic Rationale for Drug Combination Therapy

(2012) A. Siddiqui-Jain et al.   MOLECULAR CANCER THERAPEUTICS

On CK2 regulation of chronic lymphocytic leukemia cell viability

(2011) Leila R. Martins et al.   MOLECULAR AND CELLULAR BIOCHEMISTRY

Nurture versus Nature: The Microenvironment in Chronic Lymphocytic Leukemia

(2011) J. A. Burger   Hematology-American Society of Hematology Education Program

Targeting CK2 overexpression and hyperactivation as a novel therapeutic tool in chronic lymphocytic leukemia

(2010) L. R. Martins et al.   BLOOD

CX-4945, an Orally Bioavailable Selective Inhibitor of Protein Kinase CK2, Inhibits Prosurvival and Angiogenic Signaling and Exhibits Antitumor Efficacy

(2010) A. Siddiqui-Jain et al.   CANCER RESEARCH

Addiction to protein kinase CK2: A common denominator of diverse cancer cells?

(2009) Maria Ruzzene et al.   BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS

Protein Kinase CK2 in Health and Disease

(2009) J. H. Trembley et al.   CELLULAR AND MOLECULAR LIFE SCIENCES

PTEN posttranslational inactivation and hyperactivation of the PI3K/Akt pathway sustain primary T cell leukemia viability

(2008) Ana Silva et al.   JOURNAL OF CLINICAL INVESTIGATION